Daicel Corporation (BST:9DC)

Market Cap	2.10B +4.7%
Revenue (ttm)	3.19B +2.2%
Net Income	53.42M -76.9%
EPS	0.22 -76.0%
Shares Out	n/a
PE Ratio	37.32
Forward PE	n/a
Dividend	0.36 (4.45%)
Ex-Dividend Date	Sep 29, 2026

Volume	n/a
Open	8.10
Previous Close	8.10
Day's Range	8.05 - 8.20
52-Week Range	6.05 - 9.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,034
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 9DC

Financial Performance

In fiscal year 2026, Daicel's revenue was 579.63 billion, a decrease of -1.18% compared to the previous year's 586.53 billion. Earnings were 10.18 billion, a decrease of -79.43%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 30, 2026

Data Sources Report a data error